×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

Close

Choose Prolia® for your patients with glucocorticoid-induced osteoporosis at high risk for fracture.

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Learn about multiple fulfillment solutions available for your Prolia® patients.

Are your patients on glucocorticoid therapy at high risk for fracture?

Help your glucocorticoid-induced osteoporosis patients at high risk for fracture learn more
A brief fact sheet for patients helps them learn about their diagnosis and how Prolia® may help increase their bone mass.

Rapid bone mineral density (BMD) loss often begins
in the first 6 to 12 months of glucocorticoid therapy.1,2

Prolia® (denosumab) safety profile.4

Learn about adverse reactions reported in the phase 3 study of patients with glucocorticoid-induced osteoporosis.4

Adverse Reactions

Learn about the Prolia® Risk Evaluation and Mitigation Strategy Program.

REMS

Learn about Prolia® Important Safety Information.

Important Safety Information
Prolia® is
1 Shot Every
6
Months4

Single-use
prefilled 1 mL syringe

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Pregnancy must be ruled out prior to administration of Prolia®
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
  • As a subcutaneous injection, Prolia® does not undergo first-pass metabolism5
  • May lessen patient pill burden
Dosing

Important Safety Information

Following discontinuation of Prolia® treatment, fracture risk increases, including the risk of multiple vertebral fractures. Evaluate an individual’s benefit/risk before initiating treatment with Prolia®. If Prolia® treatment is discontinued, consider transitioning to an alternative antiresorptive therapy.